MetrioPharm AG
MetrioPharm AG: Realignment in financial communications
MetrioPharm AG / Miscellaneous Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- MetrioPharm AG: Realignment in financial communications Zurich, 23 September 2008: MetrioPharm AG, a biotechnology company specialising in the development and marketing of new pharmaceutical medicines in the advanced stage, has started with the realignment of its capital market communications. As a company traded on the open market, MetrioPharm AG plans to voluntarily expand its degree of transparency. Along with the publication of annual reports, interim reports are also to be prepared in German and English according to the international accounting standard IFRS. With a regular report system in the form of Corporate News and press articles, MetrioPharm AG intends to provide a prompt and comprehensive overview of current company events to its shareholders and others following the company’s progress. With regular communications and by attending capital market conferences from 2009, the company plans to expand its increasing number of investor and press contacts and at the same time raise the awareness of the company on the capital market. MetrioPharm AG is aiming to establish open and transparent capital market communications. GFEI Gesellschaft für Effekteninformation mbH, a company specialising in capital market consulting and investor relations, has been advising the company since September 2008. The company sets great store in gaining Close Brothers Seydler AG Securities Trading Bank as the designated sponsor. Since the beginning of July 2008, Close Brothers Seydler has been consistently setting exchange rates for the MetrioPharm share on the electronic trading system Xetra. 'With Close Brothers Seydler as the designated sponsor and GFEI as capital market advisor, we have made significant progress towards improving our share’s liquidity and ensuring sustainable press coverage of MetrioPharm AG. As a company traded on the open market, we are aiming for a level of transparency above that of the Entry Standard and we see releasing the interim report from 30 September 2008 as the first step towards improved communications,' explains Ekkehard Brysch, CEO at MetrioPharm AG. About MetrioPharm AG: MetrioPharm AG is a biotechnology company which specializes in the development and approval of small-molecular compounds for indications with high medical need. The company's pipeline consists of compounds in pre-clinical and clinical development for which there is already a clinical proof-of-efficacy in humans. Current lead-substances are the immune modulator MP1021 for the treatment of severe infections and inflammatory diseases as well as Etomoxir for the treatment of different forms of cardiac insufficiency. Company contact: MetrioPharm AG Neuendorfstraße 20B D-16761 Hennigsdorf www.metriopharm.com T. +49 (0) 3302 20 234 00 F. +49 (0) 3302 20 234 99 info@metriopharm.com Investor Relations contact: GFEI Gesellschaft für Effekteninformation mbH Hamburger Allee 26-28 D-60486 Frankfurt am Main www.gfei.de T. +49 (0) 69 743 037 00 F. +49 (0) 69 743 037 22 metriopharm@gfei.de 23.09.2008 Financial News transmitted by DGAP ----------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found